Document Detail

Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate.
MedLine Citation:
PMID:  22882953     Owner:  NLM     Status:  In-Data-Review    
Imatinib mesylate is a molecular targeted agent for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumor. Although imatinib mesylate is not regarded as an immunosuppressive agent, few studies have also shown that it may impair immune response. In this report, we present a case of transient hepatitis B virus (HBV) reactivation during imatinib mesylate treatment for CML.
Ya-Dan Wang; Guo-Hui Cui; Mian Li; Bhuveshwarnath Gowrea; Jia Xia; Yu Hu
Related Documents :
21075353 - Dengue virus-induced autophagy regulates lipid metabolism.
1885943 - Demonstration of concurrent dengue 1 and dengue 3 infection in six patients by the poly...
17599613 - Coxsackievirus b3 modulates cell death by downregulating activating transcription facto...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chinese medical journal     Volume:  125     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-08-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  China    
Other Details:
Languages:  eng     Pagination:  2636-7     Citation Subset:  IM    
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Breakthrough trichosporonosis in patients receiving echinocandins: case report and literature review...
Next Document:  Massive hemoptysis and hemothorax: a rare but fatal complication of intralobar sequestration.